|
rs786204041
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Tumor DNA analysis revealed TP53 pathogenic missense mutations (p.V197M, p.R213Q, p.R248W, and p.R337C) in four samples (12.9%).
|
24038938 |
2014 |
|
rs762846821
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Upregulation of pSTAT3 and phosphorylated AKT(pAKT) were observed in Kras(G12D) tumors with p53 deletion.
|
24260500 |
2013 |
|
rs55819519
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Tumors with NF1/Ch17 loss were predominantly adult GBM (4/5); lacked EGFR amplification (0/4), strong p53 immunolabeling (1/5), or IDH1 (R132H) protein expression (0/5); but expressed the mesenchymal marker podoplanin in 4/5.
|
26190195 |
2015 |
|
rs193920817
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Tumor analysis revealed two mutations: a TP53 missense mutation c.481G>A (p. Ala161Tyr) and NCOR1 nonsense mutation c.6052C>T (p. Arg2018*).
|
30039904 |
2018 |
|
rs587780076
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Tumor analysis revealed two mutations: a TP53 missense mutation c.481G>A (p. Ala161Tyr) and NCOR1 nonsense mutation c.6052C>T (p. Arg2018*).
|
30039904 |
2018 |
|
rs267605077
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results support the possibility that decreased angiogenesis might account for reduced growth rate of t</span>umor cells expressing the F134L p53 mutation.
|
16723121 |
2006 |
|
rs587782160
|
|
|
0.010 |
GeneticVariation |
BEFREE |
N131Y is likely to contribute directly to tumor phenotype and is a promising candidate biomarker of AA exposure and disease.
|
23612969 |
2013 |
|
rs746601313
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A likely pathogenic germline TP53 mutation c.760A > G (p.I254V) was found in two tumor samples and matched nontumor tissue.
|
29769598 |
2018 |
|
rs78378222
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A noncoding polymorphism (rs78378222) in TP53, carried by scores of millions of people, was previously associated with moderate risk of brain tumors and other neoplasms.
|
31699989 |
2019 |
|
rs371409680
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A total (p21 and bax) or partial (bax only) loss of transcriptional activity was observed in 15 of 52 (29%) and 4 of 52 (7.7%) cases, respectively, a partial loss being consistently associated with R283H mutation. p53 nuclear overexpression grossly overestimated (approximately 40%) or underestimated (approximately 10%) the true incidence of p53 transcriptional abnormalities, especially in Ta-T1 grade 1 to 2 tumors.
|
16000567 |
2005 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Adrenocortical tumors associated with the TP53 p.R337H germline mutation can be identified during child-care consultations.
|
28864397 |
2018 |
|
rs28934576
|
|
|
0.780 |
GeneticVariation |
BEFREE |
All three follicular cell lines, however, and the original tumor tissue showed the same p53 mutation (R273H) in MOH analysis and TGGE.
|
7725741 |
1995 |
|
rs55819519
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among the GBM cases it was noted that the IDH1 immunopositive tumors (R132H mutant protein; n=17) had a low MnSOD expression as opposed to IDH1 immunonegative tumors (n=106), which had high expression of MnSOD (p=0.0307).
|
26616112 |
2016 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An identical haplotype for p53 locus was also identified in 95% of the apparently unrelated Brazilian patients with adrenocortical tumors carrying the R337H mutation.
|
15761534 |
2004 |
|
rs1057519747
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Approximately 50% of the ovarian tumors in p53(wt/wt) mice and 23% in p53(Ala135Val/wt) mice are adenocarcinomas and the remaining tumors were adenocarcinoma mixed with sarcoma or ovarian sarcomas.
|
18234966 |
2008 |
|
rs121912665
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Approximately 50% of the ovarian tumors in p53(wt/wt) mice and 23% in p53(Ala135Val/wt) mice are adenocarcinomas and the remaining tumors were adenocarcinoma mixed with sarcoma or ovarian sarcomas.
|
18234966 |
2008 |
|
rs397516435
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Clinical targeted next-generation sequencing was performed on both neoplasms and demonstrated hemizygous stop-gain TP53 mutations (p.R196*), and wild-type SMARCA4 in both tumors.
|
28177947 |
2017 |
|
rs121912651
|
|
|
0.760 |
GeneticVariation |
BEFREE |
Common tumor mutants (R248W, R273C) were compared with the AA-associated mutants N131Y, R249W, and Q104L.
|
23612969 |
2013 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
|
28387921 |
2017 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein.
|
15741269 |
2005 |
|
rs121912664
|
|
|
0.100 |
GeneticVariation |
BEFREE |
DNA from intra-surgical specimens revealed a TP53 mutation at codon 337 (p.R337H) in samples with neoplastic cells (dysplasia, tumor and metastasis) but not in non-transformed cells (incomplete intestinal metaplasia and non-involved celiac lymph node).
|
22004116 |
2011 |
|
rs28934578
|
|
|
0.780 |
GeneticVariation |
BEFREE |
Ectopic expression of this truncated domain significantly suppressed G1/S-phase transition, cellular proliferation, and tumour formation of RK3E-p53(R175H) /Rsf-1/cyclin E1 cells.
|
23378270 |
2013 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |